Literature DB >> 18926294

The many faces of PPARgamma: anti-inflammatory by any means?

Attila Szanto1, Laszlo Nagy.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor superfamily, a group of transcription factors that regulate expression of their target genes upon ligand binding. As endogenous ligands, oxidized fatty acids and prostanoids can bind to and activate the receptor. Natural and synthetic PPARgamma activators have been studied extensively in many inflammatory settings and in most instances they have been shown to be anti-inflammatory. In this review we give an overview of the different molecular mechanisms how PPARgamma and its agonists exert their anti-inflammatory effects both at the cellular level and the level of the organism. The action of PPARgamma in acute and chronic inflammatory diseases and disease models will be presented.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926294     DOI: 10.1016/j.imbio.2008.07.015

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  70 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

2.  Peroxisome proliferator activated receptor-γ and traumatic brain injury.

Authors:  Lei Qi; Asha Jacob; Ping Wang; Rongqian Wu
Journal:  Int J Clin Exp Med       Date:  2010-09-23

Review 3.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

4.  Nitroalkene fatty acids mediate activation of Nrf2/ARE-dependent and PPARγ-dependent transcription by distinct signaling pathways and with significantly different potencies.

Authors:  Darcy J P Bates; Pamela K Smitherman; Alan J Townsend; S Bruce King; Charles S Morrow
Journal:  Biochemistry       Date:  2011-08-17       Impact factor: 3.162

Review 5.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

6.  Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women.

Authors:  Kei Hang K Chan; Tianhua Niu; Yunsheng Ma; Nai-chieh Y You; Yiqing Song; Eric M Sobel; Yi-Hsiang Hsu; Raji Balasubramanian; Yongxia Qiao; Lesley Tinker; Simin Liu
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

7.  Semantic MEDLINE for discovery browsing: using semantic predications and the literature-based discovery paradigm to elucidate a mechanism for the obesity paradox.

Authors:  Michael J Cairelli; Christopher M Miller; Marcelo Fiszman; T Elizabeth Workman; Thomas C Rindflesch
Journal:  AMIA Annu Symp Proc       Date:  2013-11-16

8.  Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family.

Authors:  Weimin Kong; Jui-Hung Yen; Evros Vassiliou; Sabina Adhikary; Miguel G Toscano; Doina Ganea
Journal:  Lipids Health Dis       Date:  2010-02-01       Impact factor: 3.876

Review 9.  Peroxisome proliferator-activated receptor (PPAR): balance for survival in parasitic infections.

Authors:  Marion M Chan; Kyle W Evans; Andrea R Moore; Dunne Fong
Journal:  J Biomed Biotechnol       Date:  2010-02-10

10.  Gene network and pathway analysis of bovine mammary tissue challenged with Streptococcus uberis reveals induction of cell proliferation and inhibition of PPARgamma signaling as potential mechanism for the negative relationships between immune response and lipid metabolism.

Authors:  Kasey M Moyes; James K Drackley; Dawn E Morin; Massimo Bionaz; Sandra L Rodriguez-Zas; Robin E Everts; Harris A Lewin; Juan J Loor
Journal:  BMC Genomics       Date:  2009-11-19       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.